Compare FSI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | MAIA |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 77.1M |
| IPO Year | 2000 | 2022 |
| Metric | FSI | MAIA |
|---|---|---|
| Price | $6.52 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.2K | ★ 642.7K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $15,494,325.00 | N/A |
| Revenue This Year | $63.39 | N/A |
| Revenue Next Year | $43.77 | N/A |
| P/E Ratio | $109.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.55 | $0.87 |
| 52 Week High | $11.48 | $3.19 |
| Indicator | FSI | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 42.77 |
| Support Level | $6.35 | $1.26 |
| Resistance Level | $7.40 | $1.47 |
| Average True Range (ATR) | 0.34 | 0.10 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 56.52 | 34.37 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.